Reimbursement News
Reimbursement news and insurance coverage updates.
Guardant Health's Shield Colorectal Cancer Blood Test Garners CMS Advanced Diagnostic Status
The test will be reimbursed at the price of $1,495 for Medicare patients during the initial nine-month ADLT period starting on April 1.
Natera MRD Test Receives MolDx Coverage for Lung Cancer Surveillance
The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.
CMS MACs Postpone Implementation of Non-Coverage Decisions for Certain Cancer Genetic Tests
The finalized local coverage determinations were set to go into effect on Feb. 23 but have been pushed back two months.
Guardant Health Reveal Assay Gets Additional Medicare Coverage for CRC Surveillance Testing
The test was previously covered for use in colorectal cancer patients in the early postsurgical setting only.
HHS Report Finds Medicare Lab Spending Dropped 5 Percent in 2023 on Lower COVID-19 Volumes
The report also indicates that while PAMA has cut spending on routine tests, overall lab spending has risen as genetic testing continues to grow.